KRAS and colorectal cancer: Ethical and pragmatic issues in effecting real-time change in oncology clinical trials and practice

Oncologist

Volumn 16, Issue 8, 2011, Pages 1061-1068

  Blanke, Charles D ^a   Goldberg, Richard M ^b   Grothey, Axel ^c   Mooney, Margaret ^d   Roach, Nancy ^e   Saltz, Leonard B ^f   John, J WELCH ^d   William, A WOOD ^b   Meropol, Neal J ^g  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c MAYO CLINIC   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e C3: Colorectal Cancer Coalition   (United States)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^g UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Clinical trials; Colorectal neoplasms; Ethics; KRAS

Indexed keywords

B RAF KINASE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; K RAS PROTEIN; OXALIPLATIN; PANITUMUMAB;

ADVANCED CANCER; ARTICLE; CANCER SURVIVAL; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; GENE MUTATION; HUMAN; MEDICAL ETHICS; MEDICAL SOCIETY; METASTASIS POTENTIAL; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; SURVIVAL TIME;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; COLORECTAL NEOPLASMS; HUMANS; MEDICAL ONCOLOGY; PHYSICIAN'S PRACTICE PATTERNS; PREDICTIVE VALUE OF TESTS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 80052210041     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2011-0011     Document Type: Article

References (24)

1. Saltz LB, Clarke S, Díaz-Rubio E et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer:Arandomized phase III study. J Clin Oncol 2008;26:2013-2019.
2. Scheithauer W, Rosen H, Kornek GV et al. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ 1993;306:752-755.
3. Committee on Cancer Clinical Trials and the NCI Cooperative Group Program; Institute of Medicine. A National Cancer Clinical Trials System for the 21st Century: Reinvigorating the NCI Cooperative Group Program. Nass SJ, Moses HL, Mendelsohn J, eds. Washington, DC: The National Academies Press, 2010:1-316.
4. Mauer AM, Rich ES, Schilsky RL. The role of cooperative groups in cancer clinical trials. In: Cancer Clinical Trials: Proactive Strategies. New York: Springer, 2007.
5. Coordinating Center for Clinical Trials, National Cancer Institute, National Institutes of Health. Transforming the NCI Clinical Trials Enterprise: Overview. Available at http://transformingtrials.cancer.gov/initiatives/overview, accessed May 5, 2011.
6. Lièvre A, Bachet JB, Le CorreDet al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006;66: 3992-3995.
7. Amado RG, Wolf M, Freeman D et al. Analysis of KRAS mutations in patients with metastatic colorectal cancer receiving panitumumab monotherapy [abstract 7LB]. Proc Eur Ca Conf 2007;5:8.
8. Amado RG, Wolf M, Peeters M et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626-1634.
9. Hecht JR, Mitchell EP, Chidiac T et al. Interim results from PACCE: Irinotecan/ bevacizumab panitumumab as first-line treatment for metastatic colorectal cancer [abstract 279]. Proc GI Symp 2008;5:208.
10. Van Cutsem E, Lang I, D'haens G et al. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer treated with FOLFIRI with or without cetuximab: The CRYSTAL experience [abstract 2]. Proc Am Soc Clin Oncol 2008;26:5s.
11. Bokemeyer C, Bondarenko I, Hartmann JT et al. KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer with FOLFOX with or without cetuximab: The OPUS experience [abstract 4000]. Proc Am Soc Clin Oncol 2008;26:178s.
12. Van Cutsem E, Nowacki M, Lang I et al. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer: The CRYSTAL trial [abstract 4000]. Proc Am Soc Clin Oncol 2007;25:164s.
13. Van Cutsem E, Köhne CH, Hitre E et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360: 1408-1417.
14. Bokemeyer C, Bondarenko I, Makhson A et al. Cetuximab plus 5-FU/FA/ oxaliplatin (FOLFOX-4) versus FOLFOX-4 in the first-line treatment of metastatic colorectal cancer: OPUS, a randomized phase II study [abstract 4035]. Proc Am Soc Clin Oncol 2007;25:172s.
15. Bokemeyer C, Bondarenko I, Makhson A et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009;27:663-671.
16. De Roock W, Jonker DJ, Di Nicolantonio F et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 2010;304: 1812-1820.
17. Peters WP, Rosner GL, Vredenburgh JJ et al. Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate- dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: A report of CALGB 9082, SWOG 9114, and NCIC MA-13. J Clin Oncol 2005;23:2191-2220.
18. Di Nicolantonio F, Martini M, Molinari F et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008;26:5705-5712.
19. Ruzzo A, Cremolini C, Loupakis F et al. Association of BRAF mutations and EGFR intron-1 L/L genotype with resistance to cetuximab plus irinotecan treatment in KRAS wild-type metastatic colorectal cancer patients [abstract 4058]. Proc Am Soc Clin Oncol 2009;27:15s.
20. Bokemeyer C, Kohne C, Rougier P et al. Cetuximab with chemotherapy as first-line treatment for metastatic colorectal cancer: Analysis of the CRYSTAL and OPUS studies according to KRAS and BRAF mutation status [abstract 3506]. Proc Am Soc Clin Oncol 2010;28:15s.
21. Van Cutsem E, Kang Y, Chung H et al. Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer [abstract LBA4509]. Proc Am Soc Clin Oncol 2009; 27:18s.
22. Punt CJ, Tol J, Rodenburg J et al. Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group [abstract LBA4011]. Proc Am Soc Clin Oncol 2008;26:1008s.
23. Presented in part at the World Congress on Gastrointestinal Cancer, Barcelona, June 25-28, 2008.
24. Karapetis CS, Khambata-Ford S, Jonker DJ et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359: 1757-1765.